Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose exploration and expansion of AMG 994 ± AMG 404 in advanced solid tumors
jRCT2031210382Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of inezetamab and zeluvalimab in Nonhematologic neoplasms, mesothelioma, pancreatic adenocarcinoma (PDAC) and 3 more (2 arms), sponsored by Amgen. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs) and Number of participants with treatment-emergent adverse events (TEAEs). Started Apr 2021; status: completed.
02
Drugs
inezetamabzeluvalimab
03
Conditions
Nonhematologic neoplasmsmesotheliomapancreatic adenocarcinoma (PDAC)Pulmonary squamous cell carcinomaNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2031210382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210382.